Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

Researchers examined the long-term natural history of branch-duct intraductal papillary mucinous neoplasms and sought to identify clinical and radiologic factors linked to developing pancreatic cancer ...

Relieving venous congestion using thrombectomy may preserve kidney function in RCC with IVC tumor thrombus.

In the PREFER trial, researchers aimed to investigate and assess the safety of strategies for fertility preservation in ...

The BOOG 2013-08 trial evaluates whether SLNB can be safely omitted for patients with clinically T1-2N0 treated with ...

The poll, conducted by NBC News Decision Desk and SurveyMonkey, found 82% of U.S. adults are satisfied with their health insurance overall. About 1 in 3 said they are very satisfied. Satisfaction was ...

In this retrospective study, researchers stratified pediatric AML patients by risk and aimed to determine whether some could receive fewer chemotherapy cycles without affecting relapse and survival ...

In this phase 3 trial, researchers aimed to study the efficacy of tumor bed boost and moderately hypofractionated whole breast irradiation in patients with non-low-risk DCIS.

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.

In this study, researchers sought to determine the impact of the FDA’s Accelerated Approval pathway among patients with solid tumors.

Identifying women eligible for lung cancer screening through screening mammography programs increases enrollment in lung cancer screening.

The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) for the treatment of adult and pediatric patients aged 2 years and older with hematopoietic stem cell transplant ...